Embed Size (px)
Citation preview
Edo Agustian
Indonesian Drug Users Network
Experiencing HCV Infection – the treatment, the reality and the
possibilities for Cure
Outline of Presentation
• Overview of hepatitis C among people who inject drugs in Indonesia
• Indonesia’s national response
• Barriers to testing and treatment access
• Advocacy and community engagement
Viral Hepatitis in Indonesia
The national response to the prevention, treatment and management of
hepatitis C among people who inject drugs
• Late response, fragmented• Indonesia does not conduct routine national surveillance • There is no national clinical guideline for diagnosis, treatment
and care for HCV• The Ministry of Health first established a national program
focused on viral hepatitis in 2011, under the Sub Directorate for Gastrointestinal Infections and Diarrheal Diseases.
Barriers to get test and treatment for Hep C in Indonesia:
• Basic principles of Human Rights are still neglected • Lack of knowledge and awareness among community,
general population and health worker• PUD’s are excluded from Indonesian National
Insurance Health Scheme• Hep C in Harm Reduction comprehensive package is
still neglected (Monitoring Quality of Harm Reduction Services by community perspective)
• Stigma (Treatment Study for co-infected HCV/HIV still excluded active DU and their under MMT)
Advocacy and community engagementSince 2011, PKNI has worked with drug users, policy-makers, and service providers to raise awareness about Hep C and ensure that the community is meaningfully involved in the national response. Highlights include:
o In 2011 conducted study : Barriers to Hep C Diagnosis, Management and Treatment among PWID in 4 Asian countries
o Training of harm reduction service providers across 9 provinceso Policy briefing on Hep Co Collaboration with Indonesian Liver Researchers Association and
Ministry of health on public Hep C campaigno Involved in developing National Guideline for Hep C Care, Support
and Treatment with MoH in 2014o Hepatitis C Community Task Force to input in MoH planningo Treatment price reductions and pharma advocacy
